Marinus Pharmaceuticals, Inc. (61Y.F)
| Previous close | 1.3400 |
| Open | 1.3600 |
| Bid | 1.3800 x N/A |
| Ask | 1.4200 x N/A |
| Day's range | 1.3600 - 1.3600 |
| 52-week range | 1.2000 - 10.2000 |
| Volume | |
| Avg. volume | 45 |
| Market cap | 77.306M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4900 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.88 |
ZacksWill Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
RADNOR, Pa., May 02, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.
Business WireMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
RADNOR, Pa., May 01, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.
